Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Acute Lymphoblastic Leukemia Specialty Channel

Acute Lymphoblastic Leukemia
Specialty Channel
News
06/21/2024
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to...
06/21/2024
Oncology
News
04/09/2024

Jordan Kadish

Jordan Kadish
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial,...
04/09/2024
Oncology
News
04/01/2024

Jordan Kadish

Jordan Kadish
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia...
04/01/2024
Oncology
FDA Approval
03/21/2024

Jordan Kadish

Jordan Kadish
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA...
03/21/2024
Oncology
News
03/15/2024

Jordan Kadish

Jordan Kadish
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis...
03/15/2024
Oncology
News
03/07/2024

Jordan Kadish

Jordan Kadish
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA...
03/07/2024
Oncology
News
02/21/2024

Jordan Kadish

Jordan Kadish
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free...
02/21/2024
Oncology
News
02/13/2024

Jordan Kadish

Jordan Kadish
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD,...
02/13/2024
Oncology
News
10/24/2023

Amber Denham

Amber Denham
The addition of a pegaspargase-modified risk-oriented program to treatment regimens improved outcomes for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia/lymphoma, according to the GIMEMA LAL1913 trial.
The addition of a pegaspargase-modified risk-oriented program to treatment regimens improved outcomes for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia/lymphoma, according to the GIMEMA LAL1913 trial.
The addition of a...
10/24/2023
Oncology
News
09/25/2023

Amber Denham

Amber Denham
Third-generation CAR-T cells for the treatment of patients with relapsed/refractory ALL were associated with promising clinical efficacy and low procedure-specific toxicity, according to the first report of a phase 1/2 trial.
Third-generation CAR-T cells for the treatment of patients with relapsed/refractory ALL were associated with promising clinical efficacy and low procedure-specific toxicity, according to the first report of a phase 1/2 trial.
Third-generation CAR-T cells for...
09/25/2023
Oncology

Advertisement

News

News
06/21/2024
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to...
06/21/2024
Oncology
News
04/09/2024

Jordan Kadish

Jordan Kadish
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial,...
04/09/2024
Oncology
News
04/01/2024

Jordan Kadish

Jordan Kadish
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia...
04/01/2024
Oncology
FDA Approval
03/21/2024

Jordan Kadish

Jordan Kadish
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA...
03/21/2024
Oncology
News
03/15/2024

Jordan Kadish

Jordan Kadish
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis...
03/15/2024
Oncology
News
03/07/2024

Jordan Kadish

Jordan Kadish
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA...
03/07/2024
Oncology
News
02/21/2024

Jordan Kadish

Jordan Kadish
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free...
02/21/2024
Oncology
News
02/13/2024

Jordan Kadish

Jordan Kadish
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD,...
02/13/2024
Oncology
News
10/24/2023

Amber Denham

Amber Denham
The addition of a pegaspargase-modified risk-oriented program to treatment regimens improved outcomes for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia/lymphoma, according to the GIMEMA LAL1913 trial.
The addition of a pegaspargase-modified risk-oriented program to treatment regimens improved outcomes for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia/lymphoma, according to the GIMEMA LAL1913 trial.
The addition of a...
10/24/2023
Oncology
News
09/25/2023

Amber Denham

Amber Denham
Third-generation CAR-T cells for the treatment of patients with relapsed/refractory ALL were associated with promising clinical efficacy and low procedure-specific toxicity, according to the first report of a phase 1/2 trial.
Third-generation CAR-T cells for the treatment of patients with relapsed/refractory ALL were associated with promising clinical efficacy and low procedure-specific toxicity, according to the first report of a phase 1/2 trial.
Third-generation CAR-T cells for...
09/25/2023
Oncology

Interactive Features

Quiz
08/01/2023
True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.
True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.
True or False: A treatment...
08/01/2023
Oncology
Quiz
03/01/2023
True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.
True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.
True or False: 3 cycles of...
03/01/2023
Oncology
Quiz
03/01/2023
True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.
True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.
True or False: The use of...
03/01/2023
Oncology
Quiz
10/05/2022
True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.
True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.
True or False: Allogeneic...
10/05/2022
Oncology
Quiz
08/23/2022
True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.
True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.
True or false: The complete...
08/23/2022
Oncology
Quiz
08/05/2022
True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...
True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...
True or False: Findings from the...
08/05/2022
Oncology
Phone
Quiz
03/07/2022
True or false: According to the phase 2 ZUMA-3 trial, brexucabtagene autoleucel may offer a treatment option for patients with R/R B-ALL.
True or false: According to the phase 2 ZUMA-3 trial, brexucabtagene autoleucel may offer a treatment option for patients with R/R B-ALL.
True or false: According to the...
03/07/2022
Oncology
Medical
Test Your Knowledge
03/07/2022
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel...
03/07/2022
Oncology
Quiz
08/09/2021
Multiple Choice: In which disease is there a global shortage of critical drugs due to supply issues?
Multiple Choice: In which disease is there a global shortage of critical drugs due to supply issues?
Multiple Choice: In which...
08/09/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement